EquityFlow
›
Companies
› TXN Systems
TXN Systems
biotech
· Solna, SE
Biotech developing a novel antibiotic for multidrug-resistant UTIs.
Funding history
Date
Round
Amount
Nov 2024
Series A
TXN Systems closed a $2.4M Series A from GU Ventures and angels to advance its EbsArgent antibiotic toward Phase I trials.
$2.4M
Investors
GU Ventures
Vasa Angels
Similar companies in biotech
Antag Therapeutics
Adcendo
Freya Biosciences
Promise Bio
Concinnity Genetics
Noema Pharma
MabGenesis
RadioNano Therapeutics
Citryll
Alveron Pharma
AQEMIA
CarboCode
Explore funding flow on EquityFlow →